InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,713.64
(
0.00%
)
US TECH 100
19,302.80
(
-0.16%
)
Dow Jones
42,025.19
(
0.00%
)
Brent Oil
73.84
(
-0.65%
)
Bitcoin
63,431.02
(
0.76%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 230

Wednesday, 07/04/2018 12:49:55 PM

Wednesday, July 04, 2018 12:49:55 PM

Post# of 438
GEMP Ph2B showed at 47% reduction in TGs with all secondary endpoints achieved.

GEMP is HOPING that these results will translate into a positive POC studies in NASH/NAFLD

Victory in NASH is likely to go to the treatment that produces the most desirable reversal in fibrosis. It's highly unlikely to be GEMP's compound.

Even so, a MC < $120mn is cheap for a company with an effective lipid treatment.

Cash runway is into 2019; but, they will need cash to run the PH3 SHTG study.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up